Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MDA-MB-134-VI | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.685 | uM | 7877.042 | 0.9827 | 0.9001 | 0.3414 | |
| MDA-MB-134-VI | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.00000175 | uM | 10077.026 | 1.2130 | 2.2409 | 0.3999 | |
| MDA-MB-134-VI | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.00000877 | uM | 10077.026 | 1.2571 | 2.5437 | 0.3999 | |
| MDA-MB-134-VI | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.0000438 | uM | 10077.026 | 1.1971 | 2.1360 | 0.3999 | |
| MDA-MB-134-VI | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.000219 | uM | 10077.026 | 1.2550 | 2.5294 | 0.3999 | |
| MDA-MB-134-VI | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.0011 | uM | 10077.026 | 1.2355 | 2.3935 | 0.3999 | |
| MDA-MB-134-VI | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.00548 | uM | 10077.026 | 1.2137 | 2.2459 | 0.3999 | |
| MDA-MB-134-VI | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.0274 | uM | 10077.026 | 1.2104 | 2.2237 | 0.3999 | |
| MDA-MB-134-VI | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.137 | uM | 10077.026 | 1.3405 | 3.1612 | 0.3999 | |
| MDA-MB-134-VI | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.685 | uM | 10077.026 | 1.0908 | 1.4854 | 0.3999 | |
| MDA-MB-157 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.00000175 | uM | 7879.018 | 1.0336 | 1.0373 | 1.7910 | |
| MDA-MB-157 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.00000877 | uM | 7879.018 | 1.0317 | 1.0352 | 1.7910 | |
| MDA-MB-157 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.0000438 | uM | 7879.018 | 0.9920 | 0.9911 | 1.7910 | |
| MDA-MB-157 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.000219 | uM | 7879.018 | 1.0604 | 1.0666 | 1.7910 | |
| MDA-MB-157 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.0011 | uM | 7879.018 | 0.9997 | 0.9997 | 1.7910 | |
| MDA-MB-157 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.00548 | uM | 7879.018 | 1.0444 | 1.0491 | 1.7910 | |
| MDA-MB-157 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.0274 | uM | 7879.018 | 1.0067 | 1.0074 | 1.7910 | |
| MDA-MB-157 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.137 | uM | 7879.018 | 1.0426 | 1.0472 | 1.7910 | |
| MDA-MB-157 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.685 | uM | 7879.018 | 0.9957 | 0.9952 | 1.7910 | |
| MDA-MB-175-VII | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.00000175 | uM | 7884.018 | 1.1044 | 1.3551 | 0.6074 | |
| MDA-MB-175-VII | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.00000877 | uM | 7884.018 | 1.0478 | 1.1597 | 0.6074 | |
| MDA-MB-175-VII | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.0000438 | uM | 7884.018 | 1.0693 | 1.2333 | 0.6074 | |
| MDA-MB-175-VII | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.000219 | uM | 7884.018 | 1.0890 | 1.3014 | 0.6074 | |
| MDA-MB-175-VII | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.0011 | uM | 7884.018 | 1.0588 | 1.1973 | 0.6074 | |
| MDA-MB-175-VII | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.00548 | uM | 7884.018 | 1.0847 | 1.2864 | 0.6074 |